Perspective Therapeutics CATX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$111.13M-30.5% | -$103.12M-30.1% | -$105.8M-65.9% | -$94.95M-60.9% | -$85.17M-45.8% | ||
| $3.65M+35.9% | $3.25M+41.0% | $2.95M+55.3% | $2.84M+90.9% | $2.68M+131% | ||
| $9.42M+38.0% | $8.97M+66.4% | $8.72M+115% | $8.51M+234% | $6.83M+126% | ||
| —— | $0— | $24.1M— | —— | —— | ||
| -$20K— | -$110K— | -$154K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $964K-65.5% | $2.01M-44.1% | $4.45M+1,003% | $4.44M+799% | $2.79M— | ||
| -$67K-104% | -$634K-132% | $677K-50.7% | $1.56M+4,485% | $1.58M+277% | ||
| $292K+101% | $331K+502% | $342K+226% | $284K— | $145K— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $1.19M— | $1.17M— | $954K— | ||
| -$92.37M-71.9% | -$82.48M-351% | -$84.43M-12,031% | -$64.78M-357% | -$53.72M-303% | ||
| $14.95M-70.1% | $12.75M-76.6% | $22.29M-44.1% | $50.01M+381% | $50M+403% | ||
| $247.57M+32.1% | $119.84M-27.3% | $264.01M— | $231.87M— | $187.38M— | ||
| $25.94M-74.2% | $0-100% | $198.4M— | $150.25M— | $100.43M— | ||
| —— | $0— | —— | —— | —— | ||
| -$62.76M+64.6% | $41.23M+119% | -$125.91M— | -$169.64M— | -$177.2M— | ||
| $54K+10.2% | $52K+8.3% | $51K+6.3% | $54K+1.9% | $49K-24.6% | ||
| $661K-99.8% | $371K-99.9% | $275.28M— | $275.7M— | $275.68M— | ||
| $164.71M+23.8% | $10.32M-96.4% | $10.66M-96.3% | $11.08M-96.2% | $133.03M-20.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $1.19M— | $1.17M— | $954K— | ||
| —— | —— | —— | —— | —— | ||
| $964K-65.5% | $2.01M-44.1% | $4.45M+1,003% | $4.44M+799% | $2.79M— | ||
| $292K+101% | $331K+502% | $342K— | $284K— | $145K— | ||
| -$67K-104% | -$634K-132% | $677K-50.7% | $1.56M+4,485% | $1.58M+277% | ||
| —— | —— | —— | —— | —— | ||
| $126K+55.6% | $135K+87.5% | $132K+363% | $117K+1,200% | $81K+500% | ||
| $199.89M+821% | $173.95M— | $119.67M— | $71.52M— | $21.7M— | ||
| $54K+10.2% | $52K+8.3% | $51K+6.3% | $54K+1.9% | $49K-24.6% | ||
| —— | —— | —— | —— | —— | ||
| $1.46M-17.7% | $205K-90.3% | $0-100% | $618K-73.2% | $1.77M+52.5% | ||
| -$107.32M-3.5% | -$95.23M-31.0% | -$106.72M-163% | -$114.78M-367% | -$103.72M-345% | ||
| -$107.32M-3.5% | -$95.23M-31.0% | -$106.72M-163% | -$114.78M-367% | -$103.72M-345% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Perspective Therapeutics generate?
- Perspective Therapeutics (CATX) generated -$92.4M in operating cash flow over the trailing twelve months.
- What is Perspective Therapeutics's free cash flow?
- After $15.0M of capital expenditures, Perspective Therapeutics's free cash flow was -$107.3M over the trailing twelve months, down 3.5% year over year.
- Where does Perspective Therapeutics's cash flow data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
